Earnings ·
Tyra Biosciences reported a net loss of $45.6 million for the quarter ended June 30, 2026, compared to $28.1 million…
TYRATyra Biosciences, Inc.
Tyra Biosciences reported a net loss of $45.6 million for the quarter ended June 30, 2026, compared to $28.1 million in the prior year period. Research and development expenses increased to $39.2 million from $24.3 million, while general and administrative costs rose to $9.8 million from $7.1 million. The company held $353.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a runway into the second half of 2028. Tyra appointed Jonathan Day as Executive Vice President of Clinical Development to lead its skeletal dysplasia strategy. The company also amended an at-the-market sales agreement with TD Securities, allowing for up to $250 million in additional share sales. Initial Phase 2 data from the SURF302 study is expected in September 2026, while BEACH301 safety sentinel cohort results are anticipated by the end of Q1 2027. Tyra Biosciences operates as a clinical-stage biotechnology company focused on developing precision medicines targeting FGFR biology.